These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35099680)

  • 1. The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis.
    Kow CSC; Ramachandram DS; Hasan SS
    Inflammopharmacology; 2022 Feb; 30(1):149-157. PubMed ID: 35099680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysis.
    Kow CS; Ramachandram DS; Hasan SS
    J Med Virol; 2022 May; 94(5):2269-2274. PubMed ID: 34978339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies.
    Kow CS; Hasan SS
    Inflammopharmacology; 2021 Aug; 29(4):1075-1090. PubMed ID: 34241782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.
    Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study.
    Kildegaard H; Lund LC; Højlund M; Stensballe LG; Pottegård A
    BMJ; 2022 Apr; 377():e068898. PubMed ID: 35410884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
    Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
    BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
    Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
    Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
    Katz MA; Harlev EB; Chazan B; Chowers M; Greenberg D; Peretz A; Tshori S; Levy J; Yacobi M; Hirsch A; Amichay D; Weinberger R; Dor AB; Taraday EK; Reznik D; Chayat CB; Sagas D; Zvi HB; Berdinstein R; Rashid G; Avni YS; Mandelboim M; Zuckerman N; Rainy N; Akriv A; Dagan N; Kepten E; Barda N; Balicer RD
    Vaccine; 2022 Jan; 40(3):512-520. PubMed ID: 34903372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
    Chico-Sánchez P; Gras-Valentí P; Algado-Sellés N; Jiménez-Sepúlveda N; Vanaclocha H; Peiró S; Burgos JS; Berenguer A; Navarro D; Sánchez-Payá J;
    Prev Med; 2022 Oct; 163():107237. PubMed ID: 36057393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021.
    Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE
    JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.
    Kyaw MH; Spinardi J; Zhang L; Oh HML; Srivastava A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2165856. PubMed ID: 36727201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population.
    Weng CH; Zhou S; Saal A; Hafferty M; McGuire DC; Chan PA
    R I Med J (2013); 2023 Feb; 106(1):26-28. PubMed ID: 36706204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.